Originorigin.bio

Origin is a Y Combinator Winter 2026 company focused on AI-driven cancer therapeutics. The company leverages advanced AI and data analytics to improve drug discovery and delivery processes.

Current cancer drug discovery is time-consuming, expensive, and often fails to deliver effective treatments. The process lacks efficient tools to analyze vast amounts of data and predict drug outcomes accurately.

Origin employs AI models to analyze complex biological data, predict drug efficacy, and optimize treatment plans. This approach accelerates the discovery phase and increases the likelihood of successful therapies.

Origin targets pharmaceutical companies, research institutions, and biotech firms seeking innovative solutions for cancer treatment development.

The company generates revenue through licensing AI models, providing consulting services, and collaborating with partners on drug development projects.

该维度暂无可核实信息（unknown）

该维度暂无可核实信息（unknown）

Advancements in AI and computational biology make it possible to tackle complex problems in drug discovery. The increasing demand for personalized cancer treatments creates a favorable market environment.